Characterization of anastrozole effects, delivered by an intravaginal ring in cynomolgus monkeys

STUDY QUESTION Is it feasible to deliver anastrozole (ATZ), an aromatase inhibitor (AI), by a vaginal polymer-based drug delivery system in the cynomolgus monkey (Macaca fascicularis) to describe the pharmacokinetic profile? SUMMARY ANSWER The present study showed the effective release of ATZ into t...

Full description

Saved in:
Bibliographic Details
Published in:Human reproduction (Oxford) 2015-02, Vol.30 (2), p.308-314
Main Authors: Rotgeri, Andrea, Korolainen, Henriikka, Sundholm, Oskari, Schmitz, Heinz, Fuhrmann, Ulrike, Prelle, Katja, Sacher, Frank
Format: Article
Language:English
Subjects:
Administration, Intravaginal
Animals
Aromatase Inhibitors - administration & dosage
Aromatase Inhibitors - adverse effects
Aromatase Inhibitors - blood
Aromatase Inhibitors - pharmacokinetics
Delayed-Action Preparations - administration & dosage
Delayed-Action Preparations - adverse effects
Delayed-Action Preparations - analysis
Delayed-Action Preparations - pharmacokinetics
Dose-Response Relationship, Drug
Down-Regulation - drug effects
Drug Delivery Systems - adverse effects
Drug Evaluation, Preclinical
Drug Implants - adverse effects
Estradiol - blood
Feasibility Studies
Female
Follicle Stimulating Hormone - blood
Half-Life
Infusions, Intravenous
Macaca fascicularis
Menstrual Cycle
Metabolic Clearance Rate
Nitriles - administration & dosage
Nitriles - adverse effects
Nitriles - blood
Nitriles - pharmacokinetics
Solubility
Triazoles - administration & dosage
Triazoles - adverse effects
Triazoles - blood
Triazoles - pharmacokinetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:STUDY QUESTION Is it feasible to deliver anastrozole (ATZ), an aromatase inhibitor (AI), by a vaginal polymer-based drug delivery system in the cynomolgus monkey (Macaca fascicularis) to describe the pharmacokinetic profile? SUMMARY ANSWER The present study showed the effective release of ATZ into the systemic circulation from intravaginal rings in cynomolgus monkeys. WHAT IS KNOWN ALREADY ATZ is a marketed drug with well documented pharmacological and safety profiles for oral administration. Aromatase is the key enzyme catalyzing estrogen biosynthesis and is overexpressed in endometriotic lesions. AIs show therapeutic efficacy in endometriosis in exploratory clinical trials. STUDY DESIGN, SIZE, DURATION The pharmacokinetics of the in vivo release and the pharmacodynamic activity of ATZ released by intravaginal rings (IVR) were investigated in healthy cycling female cynomolgus monkeys in three different dose groups (n = 5) for one menstrual cycle. PARTICIPANTS/MATERIALS, SETTING, METHODS IVRs for the cynomolgus monkey, releasing three different doses of ATZ were designed and tested for in vitro/in vivo release for up to 42 days. For pharmacokinetic and pharmacodynamic evaluation, plasma samples were taken once daily from Day 1 to 3 and then every third day until menses occurred (17–42 days). MAIN RESULTS AND THE ROLE OF CHANCE ATZ was shown to be compatible with the IVR drug delivery system. An average in vivo release of 277 µg/day/animal of ATZ for one menstrual cycle was effective in causing a decrease of systemic estradiol (E2) levels by ∼30% without inducing counter regulation such as the elevation of FSH or the formation of ovarian cysts. LIMITATIONS, REASONS FOR CAUTION The study was limited to three dose groups in which only the highest dose decreased the E2 level. Hence, additional research with IVRs releasing higher amounts of ATZ is required to define the threshold for an ATZ-dependent ovarian stimulation in cynomolgus monkeys. WIDER IMPLICATIONS OF THE FINDINGS The release rate administered from IVRs is sufficient and in a range that supports feasibility of IVR administration of ATZ as a new approach for long-term therapy of estrogen-dependent diseases such as endometriosis in human. STUDY FUNDING/COMPETING INTEREST(S) No research funding was received and none of the authors have any conflict of interests.
ISSN:0268-1161
1460-2350
DOI:10.1093/humrep/deu315